KalVista Pharmaceuticals (KALV) Cash from Operations Growth (1y) (2015 - 2025)
KalVista Pharmaceuticals (KALV) Cash from Operations Growth (1y) (2015 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - | 7.14% |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.57 Bn | 466.77 Bn | 1.35 Bn | 356.73% |
| 5 | Vertex Pharmaceuticals | 122.01 Bn | 114.76 Bn | 2.59 Bn | 74.39% |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn | 3.23% |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.86 Bn | 50.68 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.48 Bn | 34.47 Bn | 959.66 Mn | 158.60% |
| 10 | KalVista Pharmaceuticals | 1.36 Bn | 1.36 Bn | 49.41 Mn | -35.51% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | -35.51% |
| Apr 30, 2025 | -167.22% |
| Oct 31, 2024 | -99.96% |
| Jul 31, 2024 | -50.47% |
| Apr 30, 2024 | 33.27% |
| Jan 31, 2024 | -196.81% |
| Oct 31, 2023 | 3.73% |
| Jul 31, 2023 | -17.54% |
| Apr 30, 2023 | 15.50% |
| Jan 31, 2023 | 33.96% |
| Oct 31, 2022 | -5.37% |
| Jul 31, 2022 | -28.23% |
| Apr 30, 2022 | -142.54% |
| Jan 31, 2022 | -85.41% |
| Oct 31, 2021 | -145.79% |
| Jul 31, 2021 | -394.29% |
| Apr 30, 2021 | 12.47% |
| Jan 31, 2021 | 42.13% |
| Oct 31, 2020 | -1.77% |
| Jul 31, 2020 | 68.18% |